Core Viewpoint - Japan Gold Corp. has granted a 9-month extension to OR Royalties Inc. for acquiring an additional 0.5% royalty in exchange for US$3 million, extending the deadline to November 4, 2026 [1][2]. Group 1: Agreement Details - The Amending Agreement allows OR Royalties to increase their royalty interest from 1.5% to 2% by paying US$3 million [1]. - Japan Gold can accelerate the deadline if it enters into a joint venture requiring a minimum investment of C$5 million within six months [2]. - The original agreement involved OR Royalties acquiring a 1.5% net smelter return royalty for US$5 million [3]. Group 2: Company Overview - Japan Gold Corp. is focused on exploring high-grade epithermal gold deposits across Japan, holding a significant portfolio of tenements in areas with known gold occurrences [4]. - The company is recognized for its experienced leadership and operational team, which has a track record of discoveries globally [4]. - Significant shareholders include Equinox Partners Investment Management LLC and Newmont Corporation [4].

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - CVW Sustainable Royalties Inc. (TSXV: CVW) (OTCQX: CVWFF) (FSE: TMD) ("CVW Royalties" or the "Company") announces today that it has entered into a gross revenue royalty agreement ("Royalty Agreement") and strategic partnership with Relocalize Inc. ("Relocalize"), a company with a novel micro-factory technology to sustainably produce ice. Pursuant to the Royalty Agreement, CVW Royalties has agreed to provide Relocalize with $4.0 million of up-front cap ...

Core Viewpoint - Diversified Royalty Corp. has announced an agreement with underwriters to issue $50 million in 5.75% convertible unsecured subordinated debentures, with an option for an additional $7.5 million for market stabilization purposes [1][2]. Group 1: Offering Details - The debentures will mature on March 31, 2031, and will bear an annual interest rate of 5.75%, payable semi-annually starting September 30, 2026 [3]. - The conversion price for the debentures into common shares is set at $5.35 per share, subject to adjustments [3]. - The debentures are not redeemable before March 31, 2029, and can be redeemed under specific conditions thereafter [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for repaying outstanding amounts under the acquisition facility, funding additions to royalty pools, and for working capital and general corporate purposes [5]. Group 3: Recent Updates - The corporation amended its license agreements with Air Miles Loyalty Inc. and the Bank of Montreal, resulting in a fixed annual royalty payment of $3,925,000, which will grow at a rate of 2.42% per annum starting February 1, 2027 [9]. - A royalty deferral agreement with Sutton Group Realty Services Ltd. was established, allowing for a 20% deferral of royalties, which was later converted into a royalty relief agreement [10]. Group 4: Company Overview - Diversified Royalty Corp. is a multi-royalty corporation focused on acquiring top-line royalties from well-managed multi-location businesses and franchisors in North America [11]. - The corporation currently owns trademarks for several brands, including Mr. Lube + Tires, Sutton, and AIR MILES® [12]. - The objective of the corporation is to increase cash flow per share through accretive royalty purchases and to maintain a stable monthly dividend for shareholders [13].

Core Viewpoint - Gold Royalty Corp. has announced an agreement to acquire a net smelter royalty on the Borborema gold mine for a total consideration of US$45 million, which includes US$30 million in cash and newly issued common shares [1][3]. Acquisition Details - The acquisition involves a royalty rate of 1.5% on the first 1.5 million ounces of payable gold production and 1.0% until 2.0 million ounces are produced, after which there will be no royalty [2]. - The transaction is expected to be completed in January 2026, subject to customary conditions [3]. Participation of Taurus Mining Royalty Fund - Taurus Mining Royalty Fund intends to acquire a 50% economic interest in the royalty for US$22.5 million in cash, contingent upon the completion of the acquisition and finalizing a definitive participation agreement [3]. Existing Royalty Structure - Gold Royalty already holds a 2.0% net smelter return royalty on the Borborema mine, which will step down to 0.5% after 725,000 ounces of payable gold are produced [4]. Company Statements - The CEO of Gold Royalty expressed confidence in the Borborema Project and highlighted the company's strategy to expand its asset portfolio while prioritizing near-term cash flow from high-quality assets [5]. Project Background - The Borborema Project is located in the Seridó region of Brazil and is operated by Aura Minerals Inc. The mine achieved commercial production on September 22, 2025, operating at 80% of its design capacity [6][7].

Financial Data and Key Metrics Changes - The company announced a $3 billion share repurchase authorization and repurchased approximately $1 billion of stock in the first half of the year, slowing down in the third quarter due to deal flow considerations [2][3] - Return on Invested Capital (ROIC) has been consistently in the mid-teens, while Return on Equity (ROE) has been in the low 20% range, with confidence in maintaining these levels without taking on additional risks [9][10] Business Line Data and Key Metrics Changes - The company has focused on capitalizing on unique opportunities in the second half of the year, with significant transactions such as Revolution Medicines and Imdeltra contributing to deal flow momentum [3][4] - The company is open to increasing capital deployment beyond the baseline of $2 billion to $2.5 billion, driven by ongoing momentum from synthetic deals and partnerships with pharmaceutical companies [21][22] Market Data and Key Metrics Changes - The demand for customized deal structures has increased, reflecting a broader range of companies seeking partnerships, which the company is well-positioned to accommodate [5][7] - The company sees a growing appetite for capital in the biopharma industry, indicating a robust environment for future royalty opportunities [18][29] Company Strategy and Development Direction - The company aims to maintain a balanced approach to investments, focusing on both approved products with attractive growth and developmental products with significant upside potential [9][10] - The company believes that the evolution of pharma R&D partnerships will continue, with more co-funding deals expected as companies face pipeline pressures [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet and exceed capital deployment targets, emphasizing the importance of making good investments rather than rushing to deploy capital [21][22] - The company remains optimistic about the potential in various therapeutic areas, including oncology and neurodegenerative diseases, while being cautious about the risks involved [42][45] Other Important Information - The company has seen an increase in incoming deal volume since its IPO, while also proactively reaching out to early-stage companies to maintain relationships and identify opportunities [52][53] - The use of AI in the investment process is being explored, but management believes that the fundamental barriers to entry in the royalty space will remain [32][34] Q&A Session Summary Question: How does the company view the future of capital deployment? - The company anticipates a baseline capital deployment of $2 billion to $2.5 billion but is open to exceeding this based on deal flow momentum [21][22] Question: What is the company's stance on the evolving pharma R&D partnership landscape? - The company believes that pharma R&D partnerships will continue to evolve, with more co-funding deals expected due to pipeline pressures [24][26] Question: How does the company approach the use of AI in its processes? - While the company is exploring AI for due diligence and efficiency, it maintains that significant capital and experience are still required to succeed in the royalty space [32][34]

Summary of OR Royalties 2025 Investor Day Company Overview - **Company**: OR Royalties (NYSE:OR) - **Industry**: Precious metals royalty and streaming sector Key Points and Arguments Market Context - Commodities, particularly silver, have seen a price increase of 2-3%, with silver touching a 3% rise on the day of the meeting [1][2] - The company is optimistic about its growth path and shareholder returns, likening its situation to the positive outlook of sports fans [2] Business Model - OR Royalties operates as a mid-tier royalty and streaming company with a highly efficient and scalable business model [5][6] - The company has 22 producing assets out of a total of around 190, providing significant asset and cash flow diversification [5][6] - The business is insulated from inflationary pressures, boasting a 97% cash margin in the first nine months of 2025 [6] Asset Quality - The cornerstone asset, Canadian Malartic, is recognized as the best royalty in the sector, resulting from a corporate action [7] - The top three assets are operated by established companies: Agnico Eagle, Capstone Copper, and Harmony Gold [8] - 95% of gold equivalent ounces are in precious metals, with 30% of GEOs in silver [8] Financial Performance - The company has undergone significant deleveraging, reducing debt from approximately $300 million to $120 million in cash with no debt [9] - The U.S. federal government debt is at $38 trillion against a GDP of $29 trillion, leading to a debt-to-GDP ratio of about 125%, the highest since WWII [14][15] Macroeconomic Factors - Global debt levels and unsustainable deficits in major economies are expected to drive demand for gold [10][11][14][16] - Central banks are diversifying away from the U.S. dollar, contributing to a constructive environment for gold [17] Sustainability and ESG - OR Royalties integrates environmental, social, and governance (ESG) considerations into investment decisions, maintaining a prime rating by ISS ESG [24] - The company has rejected over $350 million in potential deals due to non-compliance with ESG standards [26] - Community investments have reached close to $1 million since 2021, with a focus on education, social contributions, and environmental initiatives [27] Growth Assets - **Mantos Blancos**: A key asset located in northern Chile, producing copper and silver concentrate, with a forecast of over 12,000 GEOs for the year [30] - **Dalgaranga**: Expected to be the next producing asset, with a 1.44% gross revenue royalty acquired from Remilius Resources [50] Future Outlook - The company anticipates a 40% growth in its asset base over the next five years, with no contingent capital required for this growth [20] - The phase two expansion of Mantos Blancos is expected to increase production capacity to 27,000 tons per day, with first production anticipated in late 2028 or early 2029 [43][44] Analyst Sentiment - The average target price from analysts is over $61, implying a potential gain of 36%-37% from current levels [19] Additional Important Content - The company emphasizes the importance of maintaining strong relationships with mining partners and continuously monitoring ESG commitments [26][28] - The management team has a strong average tenure of seven years, contributing to the company's operational stability [4]

Financial Data and Key Metrics Changes - Triple Flag recorded 27,000 GEOs in Q3 2025, leading to record-adjusted EBITDA of $79 million and operating cash flow per share of $0.39 [2][5] - Operating cash flow per share increased by over 25% year-over-year, reflecting strong performance amid high precious metals prices [5][6] - The company exited the quarter with essentially zero net debt and is in a net cash position, with total liquidity available of nearly $1 billion [6][7] Business Line Data and Key Metrics Changes - Northparkes and Cerro Lindo were the largest contributors to revenues in Q3, with Northparkes achieving record performance due to processing higher open-pit grades [7] - The sales mix remains 100% derived from precious metals, with nearly three-quarters from gold, and this is expected to continue [7] Market Data and Key Metrics Changes - Precious metals prices reached record quarterly averages of nearly $3,500 per ounce for gold and nearly $40 per ounce for silver [5] - The company expects to achieve 2025 GEOs between the midpoint and high end of its guidance range, benefiting from current gold prices exceeding Q3 averages [2][5] Company Strategy and Development Direction - The company has deployed over $350 million in capital across five investments year-to-date, focusing on top-tier precious metals assets in mining-friendly jurisdictions [3][4] - Recent acquisitions include a 1% NSR royalty on the Arthur project in Nevada and a royalty package on Pan American's Minera Florida gold mine in Chile for $23 million [3][4] - The company aims to continue reinvesting cash flows into further streams and royalties to enhance shareholder value over time [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's legal position regarding a $10 million owed from Step Gold, indicating ongoing discussions with the controlling shareholder [14][15] - The company anticipates near-term catalysts from various projects ramping up production, including Johnson Camp Mine and Arcata [10] - The outlook for 2029 includes expectations for 135,000-145,000 ounces GEOs, supported by ramping up of newer assets and increased production from existing mines [39] Other Important Information - The company declared a quarterly cash dividend of $5.75 per share, reflecting its strong balance sheet and cash flow generation [7] - The exploration potential of the Minera Florida mine is significant, with expectations for increased GEOs by 2028 [9] Q&A Session Summary Question: How was the Minera Florida transaction sourced? - The transaction was a concentrated process, developed through rapport with the family involved, allowing for a site visit during negotiations [12][13] Question: Update on the ATO stream and discussions with Step Gold? - The company is confident in its legal position and is in dialogue with Step's controlling shareholder, expecting to land in the top half of its guidance range regardless of the outcome [14][15] Question: Insights on transaction opportunities and structures? - The company is evaluating opportunities in the $100-$300 million range, focusing on traditional mining jurisdictions and a mix of streams and royalties [18][19] Question: Status of Priesca project and investment decisions? - The project is being staged, with the upper zones developed first, and the company will evaluate the right to fund the stream into the deeper zones when ready [26][27] Question: Discussion on El Machido stream disposal? - The situation arose from the mine being undercapitalized, and the company structured a win-win situation to allow the operator to move forward without the stream [33][34] Question: Concerns about Minera Florida's grade reconciliation issues? - Management remains confident in the long-term performance of Minera Florida, citing its historical production records despite short-term variances [37][38] Question: Confirmation on the gold-silver ratio and its impact? - The current gold-silver ratio is around 85/1, and stronger silver prices benefit the company's GEO calculations and revenue [40][41]

Financial Data and Key Metrics Changes - Triple Flag recorded 27,000 GEOs in Q3 2025, leading to record-adjusted EBITDA of $79 million and operating cash flow per share of $0.39, benefiting shareholders from higher gold prices [2][5] - Operating cash flow per share increased by over 25% year over year, with the company exiting the quarter with essentially zero net debt and a net cash position [5][6] - Total liquidity available is nearly $1 billion, allowing for continued capital deployment into growth opportunities [6] Business Line Data and Key Metrics Changes - The company has deployed over $350 million in capital across five investments year to date, including acquisitions in lithium, silver, and copper mines [3][4] - North Parks and Sarah Lindo were the largest contributors to revenues in Q3, with North Parks achieving record performance due to higher open-pit grades [6] Market Data and Key Metrics Changes - Precious metals prices reached record quarterly averages of nearly $3,500 per ounce for gold and nearly $40 per ounce for silver [5] - The sales mix remains 100% derived from precious metals, with nearly three-quarters from gold, and this is expected to continue [6] Company Strategy and Development Direction - The company focuses on top-tier precious metals assets, with nearly 90% of revenue sourced from mining-friendly jurisdictions in Australia and the Americas [6] - Future growth is supported by ongoing production ramp-ups at various mines, including Johnson Camp and Arcata, and economic studies for projects like Arthur and Hope Bay expected to complete in H1 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the high end of the 2025 GEOs guidance, with expectations for continued strong cash flows due to favorable gold prices [2][5] - The company is optimistic about the exploration potential of its assets, particularly the Minera Florida gold mine, which has a long history of consistent performance [8][9] Other Important Information - A quarterly cash dividend of $0.0575 per share was declared, reflecting the company's commitment to returning value to shareholders [6] - The company is actively evaluating transaction opportunities in the range of $100 to $300 million, focusing on jurisdictions that investors favor [21][22] Q&A Session Summary Question: How was the Minera Florida transaction sourced? - The transaction was a concentrated process, developed through rapport with the family involved, allowing for a site visit during negotiations [13][14] Question: Update on the ATO stream and discussions with Step Gold? - The company is confident in its legal position regarding a $10 million owed by Step Gold and is in dialogue with the controlling shareholder [16][17] Question: What are the current transaction opportunities? - The company is evaluating a mix of streams and royalties in traditional mining jurisdictions, with a focus on financing needs of other companies [21][22] Question: Update on Priesca project and funding decisions? - The company has the option to fund the stream into the deeps of the Priesca project when the investment decision is made, with no obligation to do so [30][31] Question: Discussion on El Machido stream disposal? - The disposal was a structured sale to allow the operator to move forward without the stream, providing good value for the company [36][37]

Financial Data and Key Metrics Changes - The company reported an 11% growth in both portfolio receipts and royalty receipts, indicating strong business momentum [4][20] - Return on invested capital was 15.7% and return on invested equity was 22.9% for the last 12 months [5][23] - Portfolio receipts for the third quarter reached $814 million, reflecting an 11% increase [20] - Full year 2025 top line guidance was raised to between $3.2 billion and $3.25 billion, representing growth of approximately 14%-16% [8][25] Business Line Data and Key Metrics Changes - The company maintained strong returns with significant contributions from Voranigo, Tremfya, and the Cystic Fibrosis Franchise [20] - The development stage pipeline expanded to 17 therapies, with multiple pivotal readouts expected in the near future [7][14] Market Data and Key Metrics Changes - The company is actively participating in the growing market for royalties, with recent acquisitions including a royalty interest in Amgen's Imdelltra and Alnylam's AMVUTTRA [6][10] - The company has seen a significant uptick in deal activity, with a total of approximately $1.6 billion in announced value across three different disease areas [9] Company Strategy and Development Direction - The company aims to be the premier capital allocator in life sciences, focusing on innovative therapies with high patient impact [4][13] - The strategy includes a therapy area agnostic investment approach, allowing the company to invest across various disease areas [15][16] - The company is committed to creating value for shareholders through investments in innovative therapies [13][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the external environment, noting that increased biotech M&A activity could benefit their capital allocation strategy [38] - The company is excited about growth opportunities in China, particularly in out-licensing deals with multinationals [39] - Management emphasized the stability and consistency of their return metrics, indicating confidence in maintaining attractive returns [48][23] Other Important Information - The company has returned a record $1.5 billion to shareholders in the first nine months of the year, including share repurchases and dividends [24][25] - The company maintains financial flexibility with cash and equivalents of $939 million and access to a $1.8 billion revolver [23][24] Q&A Session Summary Question: Impact of biotech M&A and interest rates on royalty-driven deal activity - Management noted that increased M&A activity does not significantly impact their operations and that they see it as beneficial for capital needs in the sector [38][39] Question: Frequency of collaborations with large pharma - Management indicated that as the largest royalty buyer, they are actively looking at all deals and see a growing opportunity for using royalties to fund trials with both biotech and big pharma [41][42] Question: Insights on AMVUTTRA deal and competition - Management highlighted their confidence in AMVUTTRA's potential despite competition from Nucresiran, emphasizing their thorough analysis of various scenarios [51][55] Question: Implications of trial designs in the LP(a) space - Management acknowledged differences in trial designs and expressed optimism about both Amgen's and Novartis's trials, maintaining a positive outlook on their investments in this area [67][75] Question: Updates on obexelimab and its market potential - Management confirmed that the recent phase II data for obexelimab validated their investment thesis and highlighted the focus on IgG4-related disease for near-term capital needs [77][76]

Financial Data and Key Metrics Changes - The company reported an 11% growth in both portfolio receipts and royalty receipts, indicating strong business momentum [4][22] - Return on invested capital was 15.7% and return on invested equity was 22.9% for the last 12 months [6][25] - Portfolio receipts for Q3 2025 reached $814 million, reflecting an 11% increase [22] Business Line Data and Key Metrics Changes - The company maintained strong growth driven by key products such as Voranigo, Tremfya, and the Cystic Fibrosis Franchise [22] - The development stage pipeline expanded to 17 therapies, with multiple pivotal readouts expected in the near future [7][15] Market Data and Key Metrics Changes - The company raised its full-year 2025 top line guidance to between $3.2 billion and $3.25 billion, representing growth of approximately 14-16% [9][20] - Milestones and other contractual receipts are now expected to be around $125 million, up from $110 million previously [20] Company Strategy and Development Direction - The company aims to be the premier capital allocator in life sciences, focusing on innovative therapies with high patient impact [4][31] - The strategy includes a therapy area agnostic investment approach, allowing for diversification across various disease areas [10][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for funding life sciences innovation, highlighting the potential for annualized total shareholder returns in the mid-teens over the next five years [31] - The company is excited about growth opportunities in China, particularly in out-licensing to multinationals [39] Other Important Information - The company deployed $1 billion in capital for value-creating royalty transactions in Q3 2025, totaling $1.7 billion for the first nine months [6][26] - Share repurchases amounted to $1.15 billion in the first nine months of 2025 [26] Q&A Session Summary Question: Impact of biotech M&A and interest rates on royalty-driven deal activity - Management noted that the uptick in M&A activity does not significantly impact their operations, as large pharma companies require capital, which the company provides [38] Question: Thoughts on the China opportunity - Management is optimistic about growth in China and is actively building relationships to capitalize on this market [39] Question: Frequency of collaborations with large pharma - Management believes the use of royalties to fund trials is becoming mainstream, indicating a growing opportunity in this area [41] Question: Insights on the Amvuttra deal and competition - Management expressed confidence in the Amvuttra investment despite potential competition from Nucresiran, citing a broad range of scenarios considered [60] Question: Updates on the LP(a) space and trial designs - Management acknowledged differences in trial designs and remains optimistic about the prospects of their investments in this area [90] Question: Updates on obexelimab and its market potential - Management highlighted the strong phase 2 data for obexelimab, validating its potential in treating autoimmune diseases [92]